Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers.
Target Price
The average target price of ELDN is 8.1 and suggests 110% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell